
    
      The standard treatment in patients with refractory or relapsed diffuse large B-cell lymphoma
      is salvage chemotherapy followed by autologous transplantation for responsive patients.
      However, the standard of salvage chemotherapy remains uncertain. This study is to evaluate
      the efficacy and safety of R-ESHAP regimen in a multi-center basis.
    
  